About Sight Sciences, Inc.
https://www.sightsciences.comSight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases.
CEO
Paul Badawi
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 53
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
UBS
Buy
Lake Street
Buy
Stifel
Buy
Morgan Stanley
Equal Weight
Citigroup
Neutral
Piper Sandler
Neutral
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
KCK LTD.
Shares:4.37M
Value:$30.14M
LONG FOCUS CAPITAL MANAGEMENT, LLC
Shares:3.19M
Value:$22M
BLACKROCK, INC.
Shares:2.54M
Value:$17.52M
Summary
Showing Top 3 of 89
About Sight Sciences, Inc.
https://www.sightsciences.comSight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $19.91M ▲ | $25.1M ▼ | $-8.17M ▲ | -41.04% ▲ | $-0.16 ▲ | $-6.84M ▲ |
| Q2-2025 | $19.56M ▲ | $28.25M ▼ | $-11.94M ▲ | -61.04% ▲ | $-0.23 ▲ | $-10.49M ▲ |
| Q1-2025 | $17.51M ▼ | $28.95M ▲ | $-14.15M ▼ | -80.84% ▼ | $-0.28 ▼ | $-12.7M ▼ |
| Q4-2024 | $19.07M ▼ | $28.49M ▲ | $-11.85M ▼ | -62.11% ▼ | $-0.23 ▼ | $-10.47M ▼ |
| Q3-2024 | $20.16M | $28.14M | $-11.07M | -54.9% | $-0.22 | $-9.59M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $92.37M ▼ | $116.26M ▼ | $51.97M ▲ | $64.29M ▼ |
| Q2-2025 | $101.5M ▼ | $121.97M ▼ | $51.96M ▼ | $70.01M ▼ |
| Q1-2025 | $108.77M ▼ | $129.68M ▼ | $52.05M ▼ | $77.63M ▼ |
| Q4-2024 | $120.36M ▲ | $142.84M ▼ | $55.32M ▲ | $87.52M ▼ |
| Q3-2024 | $118.56M | $143.6M | $48.64M | $94.96M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-8.17M ▲ | $-8.72M ▼ | $-170K ▲ | $25K ▼ | $-8.86M ▼ | $-8.89M ▼ |
| Q2-2025 | $-11.94M ▲ | $-7.54M ▲ | $-210K ▼ | $485K ▲ | $-7.27M ▲ | $-7.75M ▲ |
| Q1-2025 | $-14.15M ▼ | $-11.61M ▼ | $0 ▲ | $16K ▼ | $-11.59M ▼ | $-11.61M ▼ |
| Q4-2024 | $-11.85M ▼ | $-3.46M ▼ | $-137K ▼ | $5.39M ▲ | $1.79M ▲ | $-3.6M ▼ |
| Q3-2024 | $-11.07M | $600K | $-51K | $-162K | $387K | $549K |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Dry Eye | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Surgical Glaucoma | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
CEO
Paul Badawi
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 53
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
UBS
Buy
Lake Street
Buy
Stifel
Buy
Morgan Stanley
Equal Weight
Citigroup
Neutral
Piper Sandler
Neutral
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
KCK LTD.
Shares:4.37M
Value:$30.14M
LONG FOCUS CAPITAL MANAGEMENT, LLC
Shares:3.19M
Value:$22M
BLACKROCK, INC.
Shares:2.54M
Value:$17.52M
Summary
Showing Top 3 of 89